Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25465262 | 0.80 | TGM2 (0.35) | TDP1ALDH1A1MGLLMEN1KMT2A | |
| SCHEMBL181071 | 0.80 | FOLH1 (0.37) | ALDH1A1CNR1CNR2HPGDHSD17B10 | |
| SCHEMBL21538842 | 0.79 | MEN1 (0.33) | ALDH1A1HPGDMGLLMEN1KMT2A | |
| SCHEMBL18751703 | 0.79 | MGLL (0.33) | TDP1MGLLKMT2ASMN1; SMN2 | |
| SCHEMBL17776064 | 0.79 | MGLL (0.33) | TDP1MGLLKMT2ASMN1; SMN2 | |
| SCHEMBL17776136 | 0.79 | MGLL (0.33) | TDP1MGLLKMT2ASMN1; SMN2 | |
| SCHEMBL855021 | 0.79 | MGLL (0.33) | TDP1MGLLKMT2ASMN1; SMN2 | |
| SCHEMBL15289811 | 0.78 | DRD2 (0.48) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21731479 | 0.78 | MAP3K7 (0.34) | TDP1ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL18297142 | 0.78 | DRD2 (0.48) | ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 757 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-09-05 | — | — | US | claimed |
| US-11712423-B2 | Methods and compositions for modifying mucous membranes | ABBOTT NICHOLAS L (US) | 2023-08-01 | — | — | US | claimed |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | claimed |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-01-13 | — | — | US | claimed |
| EP-3799883-A1 | NOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GlaxoSmithKline Biologicals S.A. (BE) | 2021-04-07 | — | — | EP | claimed |
| EP-3664837-A1 | MULTI-FUNCTIONALIZED nOMV CONJUGATES | GlaxoSmithKline Biologicals S.A. (BE) | 2020-06-17 | — | — | EP | claimed |
| WO-2019030271-A1 | MULTI-FUNCTIONALIZED nOMV CONJUGATES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-02-14 | — | — | WO | claimed |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2018-09-20 | — | — | US | claimed |
| WO-2015017316-A2 | METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANES | ABBOTT NICHOLAS L (US) | 2015-02-05 | — | — | WO | claimed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | claimed |
| EP-2171457-B1 | IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES | INNOVA BIOSCIENCES LTD (GB) | 2013-07-10 | — | — | EP | claimed |
| US-20120270787-A1 | COMPOUNDS HAVING PEPTIDES CONJUGATED TO BONE TARGETING MOIETIES AND METHODS OF MAKING AND USING THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-10-25 | — | — | US | claimed |
| CN-101790684-A | Improvements in or relating to the preparation of conjugates | INNOVA BIOSCIENCES LTD | 2010-07-28 | — | — | CN | claimed |
| US-20100184184-A1 | Production of Conjugates | INNOVA BIOSCIENCES LIMITED (GB) | 2010-07-22 | — | — | US | claimed |
| EP-2171457-A2 | IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES | Innova Biosciences Limited (GB) | 2010-04-07 | — | — | EP | claimed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | claimed |
| WO-2008152424-A2 | IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES | INNOVA BIOSCIENCES LIMITED (GB) | 2008-12-18 | — | — | WO | claimed |
| US-20030148304-A1 | Method for immobilisation | KAROLINSKA INNOVATIONS AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1235937-A1 | METHOD FOR IMMOBILISATION | Karolinska Innovations AB (SE) | 2002-09-04 | — | — | EP | claimed |
| WO-2001042501-A1 | METHOD FOR IMMOBILISATION | KAROLINSKA INNOVATIONS AB (SE) | 2001-06-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270787-A1 | COMPOUNDS HAVING PEPTIDES CONJUGATED TO BONE TARGETING MOIETIES AND METHODS OF MAKING AND USING THEREOF | SOST, CALCRL, CALCA | TDP1 2295/4885ALDH1A1 4538/4885CNR1 3652/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | TDP1 4742/4885ALDH1A1 3404/4885CNR1 1065/4885 |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | VAPB, CD14, CHMP4B | TDP1 4232/4885ALDH1A1 4669/4885CNR1 4654/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | TDP1 4742/4885ALDH1A1 3404/4885CNR1 1065/4885 |
| US-20240293524-A1 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | CD14, VAPB, CHMP4B | TDP1 4120/4885ALDH1A1 4653/4885CNR1 4593/4885 |
| US-20220008529-A1 | MULTI-FUNCTIONALIZED noMV CONJUGATES | CD14, CHMP4B, VAPB | TDP1 4095/4885ALDH1A1 4555/4885CNR1 4599/4885 |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | TDP1 4547/4885ALDH1A1 3966/4885CNR1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.